Renal interaction between itraconazole and cimetidine

Journal of Clinical Pharmacology

Volumn 44, Issue 8, 2004, Pages 919-927

  Karyekar, Chetan S ^b   Eddington, Natalie D ^b   Briglia, Andrew ^b   Gubbins, Paul O ^b   Dowling, Thomas C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NONE

Author keywords

Cimetidine; Itraconazole; Renal drug interactions; Renal tubular secretion

Indexed keywords

CIMETIDINE; CREATININE; GLYCOPROTEIN P; IOTALAMIC ACID; ITRACONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG EXCRETION; DRUG URINE LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; MALE; NORMAL HUMAN;

ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CIMETIDINE; DRUG INTERACTIONS; FEMALE; GLOMERULAR FILTRATION RATE; HALF-LIFE; HISTAMINE H2 ANTAGONISTS; HUMANS; IOTHALAMIC ACID; ITRACONAZOLE; KIDNEY TUBULES; MALE; P-GLYCOPROTEIN;

EID: 3242784679     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266783     Document Type: Article

References (37)

1. Yu DK: The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999;39:1203-1211.
2. Giacomini KM: Membrane transporters in drug disposition. J Pharmacokinet Biopharm 1997;25:731-741.
3. Berkhin EB, Humphreys MH: Regulation of renal tubular secretion of organic compounds. Kidney Int 2001;59:17-30.
4. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
5. Ernest S, Rajaram S, Megyesi J, Bello-Reuss E: Expression of MDR1 gene and its protein in normal human kidney. Nephron 1997; 77:284-289.
6. Ito S, Woodland C, Koren G: Characteristics of itraconazole and ketoconazole inhibition of digoxin transport across renal tubular cells. FASEB J 1995;9:A686.
7. Ito S, Woodland C, Sarkadi B, Hockmann G, et al: Modeling of P-gp involved epithelial drug transport in MDCK cells. Am J Physiol 1999; 277:F84-F96.
8. Horio M, Pastan I, Gottesman M, Handler J: Transepithelial transport of vinblastine by kidney-derived cell lines. Biochim Biophys Acta 1990;1027:116-122.
9. Decorti G, Peloso I, Favarin D, Baldini L: Handling of doxorubicin by the LLCPK1 kidney cell line. J Pharmacol Exp Ther 1998;286: 525-530.
10. Pedersen PV, Miller R: Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 1980;69:394-398.
11. Berardi RR, Tankanow RM, Nostrant TT: Comparison of famotidine with cimetidine and ranitidine. Clin Pharm 1988;7:271-284.
12. Somogyi A, Gugler R: Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 1983;8:463-495.
13. Pan BF, Dutt A, Nelson JA: Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein. J Pharmacol Exp Ther 1994;270:1-7.
14. Dutt A, Heath LA, Nelson JA: P-glycoprotein and organic cation secretion by the mammalian kidney. J Pharmacol Exp Ther 1994; 269:1254-1260.
15. Wang EJ, Casciano CN, Clement RP, Johnson WW: Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 2001;18:432-438.
16. Kurosawa M, Okabe M, Hara N, Kawamura K, Suzuki S, Sakurada K: Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Ann Hematol 1996;72:17-21.
17. Gupta S, Kim J, Gollapudi S: Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. J Clin Invest 1991;87:1467-1469.
18. Jalava KM, Partanen J, Neuvonen PJ: Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997;19:609-613.
19. Kaukonen KM, Olkkola KT, Neuvonen PJ: Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 1997;62: 510-517.
20. Dowling TC, Frye RF, Zemaitis MA: Simultaneous determination of p-aminohippuric acid, acetyl-p-aminohippuric acid and iothalamate in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998;716:305-313.
21. Iqbal T, Karyekar CS, Kinjo M, Ngan GC, Dowling TC: Validation of a simplified method for determination of cimetidine in human plasma and urine by liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 2004;799(2):337-341.
22. Gubbins PO, Gurley BJ, Bowman J: Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J Pharm Biomed Anal 1998;16:1005-1012.
23. Ernest S, Bello-Reuss E: P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. Kidney Int Suppl 1998;65: S11-S17.
24. Karyekar CS, Eddington ND, Garimella TS, Gubbins PO, Dowling TC: Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model. Pharmacotherapy 2003;23:436-442.
25. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 1996;118:1841-1847.
26. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA: The effect of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994; 74:824-841.
27. Sonneveld P, Marie JP, Vekhoff A, Schoester M, Faussat AM, Groenewegen A, et al: Reversal of multidrug resistance by PSC833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase I study. Leukemia 1996;10: 1741-1750.
28. Somogyi A: Renal transport of drugs: specificity and molecular mechanisms. Clin Exp Pharmacol Physiol 1996;23:986-989.
29. VanGinneken CA, Russel GA: Saturable pharmacokinetics in the renal excretion of drugs. Clin Pharmacokinet 1989;16:38-54.
30. Horio M, Chin KV, Currier SJ, Goldenberg S, Williams C, Pastan I, et al: Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 1989;264:14880-14884.
31. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-871.
32. Gutmann H, Fricker G, Torok M, Michael S, Beglinger C, Drewe J: Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res 1999;16:402-407.
33. Pavelic ZP, Reising J, Pavelic L, Kelley DJ, Stambrook PI, Gluckman JL: Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch Otolaryngol Head Neck Surg 1993;119:753-757.
34. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab 2000; 1(2):181-191.
35. Varis T, Kivisto KT, Backman JT, Neuvonen PJ: The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000;68:487-494.
36. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, et al: Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl) 1998; 139:269-273.
37. Kimelblatt BJ, Cerra FB, Calleri G, Berg MJ, McMillen MA, Schentag JJ: Dose and serum concentration relationships in cimetidine-associated mental confusion. Gastroenterology 1980;78: 791-795.